Sugi Predict

Sugi Predict / Compounds / SCHEMBL1541156

SCHEMBL1541156

SCHEMBL1541156

O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccc(OC(F)(F)F)cc2)c([N+](=O)[O-])c1)c1ccc(N2CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC2)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCL2L1 Q07817 16/20 0.76
▸ BCL2 P10415 10/20 0.76
▸ MDM4 O15151 1/20 0.72
▸ BCL2L11 O43521 1/20 0.72
▸ TP53 P04637 1/20 0.72
▸ BID P55957 1/20 0.72
▸ BAX Q07812 1/20 0.72
▸ MCL1 Q07820 1/20 0.72
▸ ASPH Q12797 1/20 0.72
▸ BECN1 Q14457 1/20 0.72
▸ BAK1 Q16611 1/20 0.72
▸ BCL2L2 Q92843 1/20 0.72
▸ BAD Q92934 1/20 0.72
▸ BBC3 Q9BXH1 1/20 0.72
▸ HDAC3 O15379 3/20 0.68
▸ HDAC4 P56524 3/20 0.68
▸ HDAC1 Q13547 3/20 0.68
▸ HDAC7 Q8WUI4 3/20 0.68
▸ HDAC2 Q92769 3/20 0.68
▸ HDAC10 Q969S8 3/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1540646 0.96 BCL2L1 (0.74) BCL2L1BCL2MDM4BCL2L11TP53
SCHEMBL1540658 0.94 BCL2L1 (0.83) BCL2L1BCL2MDM4BCL2L11TP53
SCHEMBL1541602 0.93 BCL2L1 (0.78) BCL2L1BCL2MDM4BCL2L11TP53
SCHEMBL1541210 0.93 BCL2L1 (0.79) BCL2L1BCL2MDM4BCL2L11TP53
SCHEMBL1540264 0.93 BCL2L1 (0.86) BCL2L1BCL2MDM4BCL2L11TP53
SCHEMBL19424462 0.92 BCL2L1 (0.78) BCL2L1BCL2
SCHEMBL1540923 0.92 BCL2L1 (0.86) BCL2L1BCL2MDM4BCL2L11TP53
SCHEMBL1540310 0.92 BCL2L1 (0.80) BCL2L1BCL2MDM4BCL2L11TP53
SCHEMBL1540475 0.89 BCL2L1 (0.76) BCL2L1BCL2MDM4BCL2L11TP53
SCHEMBL1540604 0.89 BCL2L1 (0.83) BCL2L1BCL2MDM4BCL2L11TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3048098-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS AbbVie Bahamas Limited (BS) 2016-07-27 — — EP claimed
US-8354404-B2 Apoptosis promoters ABBOTT LABORATORIES (US) 2013-01-15 — — US claimed
US-20110256129-A1 APOPTOSIS PROMOTERS ABBOTT LABORATORIES 2011-10-20 — — US claimed
US-10195213-B2 Chemical entities that kill senescent cells for use in treating age-related disease UNITY BIOTECHNOLOGY, INC. (US) 2019-02-05 — — US disclosed
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES UNITY BIOTECHNOLOGY, INC. 2017-10-05 — — US disclosed
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES UNITY BIOTECHNOLOGY, INC. 2017-10-05 — — US disclosed
EP-3048098-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS AbbVie Bahamas Limited (BS) 2016-07-27 — — EP disclosed
US-20160175316-A1 METHOD OF PREVENTING OR TREATING ORGAN, HEMATOPOIETIC STEM CELL OR BONE MARROW TRANSPLANT REJECTION ABBVIE INC (US) 2016-06-23 — — US disclosed
US-20160101109-A1 METHOD OF TREATING ARTHRITIS ABBVIE INC. 2016-04-14 — — US disclosed
EP-1685119-B1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBVIE BAHAMAS LTD (BS) 2016-03-09 — — EP disclosed
US-9045444-B2 Apoptosis promoters ABBVIE INC. (US) 2015-06-02 — — US disclosed
US-7642260-B2 N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide ABBOTT LABORATORIES, INC. (US) 2010-01-05 — — US disclosed
US-20090176785-A1 METHOD OF TREATING ARTHRITIS ABBOTT LABORATORIES (US) 2009-07-09 — — US disclosed
US-20080182845-A1 METHOD OF PREVENTING OR TREATING ORGAN, HEMATOPOIETIC STEM CELL OR BONE MARROW TRANSPLANT REJECTION ABBOTT LABORATORIES (US) 2008-07-31 — — US disclosed
US-20080076779-A1 Reducing platelets in mammals blood and preventing/treating pro-thrombotic conditions and diseases via inhibitors of anti-apoptotic Bcl-2 family protein members ABBVIE INC. 2008-03-27 — — US disclosed
US-20070072860-A1 N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide ABBOTT LABORATORIES 2007-03-29 — — US disclosed
US-20070015787-A1 Apoptosis promoters ABBVIE INC. 2007-01-18 — — US disclosed
US-20060258657-A1 Apoptosis promoters ABBVIE INC. 2006-11-16 — — US disclosed
US-20060128706-A1 Apoptosis promoters ABBVIE INC. 2006-06-15 — — US disclosed
US-20050159427-A1 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES 2005-07-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES TP53, NQO1, SHMT2 BCL2L1 953/4885BCL2 520/4885MDM4 630/4885
US-20060128706-A1 Apoptosis promoters BAX, BCL2, API5 BCL2L1 10/4885BCL2 2/4885MDM4 1269/4885
US-20070015787-A1 Apoptosis promoters BAX, BCL2, API5 BCL2L1 10/4885BCL2 2/4885MDM4 1269/4885
US-20160101109-A1 METHOD OF TREATING ARTHRITIS MMP1, COL2A1, MMP13 BCL2L1 1304/4885BCL2 147/4885MDM4 2663/4885
US-20060258657-A1 Apoptosis promoters BAX, BCL2, API5 BCL2L1 10/4885BCL2 2/4885MDM4 1269/4885
US-20050159427-A1 N-acylsulfonamide apoptosis promoters BAX, API5, CCAR2 BCL2L1 20/4885BCL2 4/4885MDM4 2603/4885
US-20080076779-A1 Reducing platelets in mammals blood and preventing/treating pro-thrombotic conditions and diseases via inhibitors of anti-apoptotic Bcl-2 family protein members BCL2, BAX, BCLAF1 BCL2L1 7/4885BCL2 1/4885MDM4 4169/4885
US-20090176785-A1 METHOD OF TREATING ARTHRITIS MMP1, COL2A1, MMP13 BCL2L1 1304/4885BCL2 147/4885MDM4 2663/4885
US-10195213-B2 Chemical entities that kill senescent cells for use in treating age-related disease TP53, CDKN1A, GLA BCL2L1 464/4885BCL2 132/4885MDM4 441/4885
US-20070072860-A1 N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide BCL2A1, BAX, BCL2L1 BCL2L1 3/4885BCL2 4/4885MDM4 1653/4885
US-20080182845-A1 METHOD OF PREVENTING OR TREATING ORGAN, HEMATOPOIETIC STEM CELL OR BONE MARROW TRANSPLANT REJECTION BST2, HLA-C, HLA-B BCL2L1 233/4885BCL2 94/4885MDM4 2097/4885
US-20160175316-A1 METHOD OF PREVENTING OR TREATING ORGAN, HEMATOPOIETIC STEM CELL OR BONE MARROW TRANSPLANT REJECTION BST2, HLA-C, HLA-B BCL2L1 233/4885BCL2 94/4885MDM4 2097/4885
US-20110256129-A1 APOPTOSIS PROMOTERS BAX, BCL2, API5 BCL2L1 10/4885BCL2 2/4885MDM4 1269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.